

Weigh Special Issues in Immunocompromised Kids

BY JANE SALODOF MACNEIL
Southwest Bureau

ASPEN, COLO. — Two groups of immunocompromised children present special challenges in community-based practices, Elizabeth J. McFarland, M.D., said at a conference on pediatric infectious diseases, sponsored by Children's Hospital, Denver.

Weakened immune systems can make some vaccinations worrisome for young-

sters taking high-dose steroids to control asthma or rheumatic diseases and can make other vaccinations vital for children without a spleen, said Dr. McFarland, director of the hospital's immunodeficiency clinic.

Even more serious, she warned, is the risk of sepsis, with high mortality rates from postsplenectomy sepsis. One-half of sepsis cases occur within 2 years of spleen removal, but 3% have been documented 20 years afterward (Br. J. Surg. 1991;78:1031-8).

Steroid Concerns

Dr. McFarland acknowledged that steroids are "important drugs" for controlling inflammation. The problem is that by interfering with cytokine production and lessening immune cell activity, steroids reduce the body's "ability to mount immune response or react to vaccine."

According to Dr. McFarland, the American Academy of Pediatrics supports giving inactivated virus vaccines to children who are prescribed steroids, but she cau-

tions that immunogenicity is uncertain. Live virus vaccines should be delayed until high-dose steroids are stopped.

If children take a high-dose steroid daily or on alternate days for more than 14 days, doctors should wait 1 month after stopping steroid use before giving vaccines, Dr. McFarland said. She also said that if the dosage period is less than 14 days, live virus vaccines can be given after stopping, but some experts recommend waiting 2 weeks.

AAP recommends inactivated influenza vaccine for patients with asthma. Dr. McFarland said studies have shown similar antibody responses to the influenza vaccine in patients receiving inhaled steroids and short-course oral steroids, when compared with patients not receiving steroids at the time of immunization.

The live varicella zoster virus (VZV) vaccine is not recommended during high-dose steroid use, because vaccine safety is not established in this population. How-

If children take a high-dose steroid daily or on alternate days for more than 14 days, wait 1 month after stopping steroid use before giving vaccines.

ever, Dr. McFarland said a health maintenance organization study found that inhaled steroids given 3 months prior to VZV vaccination were not associated with increased risk of breakthrough disease (Pediatrics 2003;

112:e98-e113), but the study did find increased breakthrough disease after VZV vaccination when oral steroids were given in the 3 months prior.

Postsplenectomy Issues

European studies have shown that about a quarter of physicians do not comply with guidelines for postsplenectomy care, Dr. McFarland said. She could not find any similar studies in the United States.

Although splenectomies in children may be necessary after trauma, she said the operation is being done less often owing to greater recognition of the spleen's importance to immune defense and to newer splenic salvage techniques.

Dr. McFarland urged pneumococcal vaccination for postsplenectomy patients. About two-thirds of sepsis cases have been traced to *Streptococcus pneumoniae* in this population.

If the regular pneumococcal conjugate vaccine (PCV) series was not given before age 24 months, doctors should give two doses of PCV, she said. She recommended one dose of pneumococcal polysaccharide vaccine 6-8 weeks after PCV, and a second dose 3-5 years afterward.

Postsplenectomy patients also should be vaccinated against meningococcus, according to Dr. McFarland. The new meningococcal conjugate vaccine (MCV4) is preferred for patients aged 11-55; only meningococcal polysaccharide vaccine (MPSV4) is approved for patients aged 2-

Continued on following page

LAUNCHING NOVEMBER 2005

nature
CLINICAL
PRACTICE

RHEUMATOLOGY

Editor-in-Chief: Peter E. Lipsky, MD



A new journal from the publishers of *Nature*, **Nature Clinical Practice Rheumatology** delivers timely, authoritative interpretations of key research developments, translating the latest findings into clinical practice.

Articles include editorials and opinion pieces from leading authorities, highlights from the current literature, expert commentaries on the application of recent research findings to practical patient care, comprehensive reviews, and in-depth case studies.

Our Editor-in-Chief, Peter E. Lipsky, MD, and an international Advisory Board ensure broad coverage across the specialty of current developments throughout the year, reflecting the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.

Only \$96 per year (12 issues) for a personal subscription in print and online.

Visit us online at: www.nature.com/clinicalpractice for more information and to subscribe at a **special 25% discount**.

To receive your 25% discount when subscribing online please do the following:

- 1 Go to www.nature.com/clinicalpractice.
- 2 Click "SUBSCRIBE" at the upper right.
- 3 Click the journal title.
- 4 Enter the special offer code 5R1105DNG in the space provided.
- 5 Click "Update Price".
- 6 Click "Continue to Payment" and enter your payment details as indicated.

www.nature.com/clinicalpractice

nature publishing group 

Continued from previous page

11. Optimally, vaccinations for the encapsulated bacteria should be given prior to a planned splenectomy.

She suggested giving an extra dose of *Haemophilus influenzae* type b (Hib) vaccine

Teach Parents About Zoonoses

Many physicians—Dr. McFarland among them—do not have the heart to banish all pets from the home of an immunocompromised child.

“The better you can take care of your animal ... the less likely your pet will get sick,” is the message she urged physicians to give to parents of immunocompromised patients. Keeping the animal healthy will help the child stay well.

Dr. McFarland said the U.S. Public Health Service has identified five zoonoses of particular concern that immunocompromised children can pick up from animals: salmonellosis, campylobacteriosis, bacillary angiomatosis (*Bartonella henselae*, or cat scratch disease), cryptosporidiosis, and toxoplasmosis.

She also summarized the benefits of pet ownership, including decreased loneliness and increased feeling of intimacy and constancy.

The first principle of pet safety, she said, is to buy or adopt a healthy animal, preferably an adult. Young animals are more vulnerable to pathogens. No animal with diarrhea should be handled by the child.

Second, keep the animal healthy by preventing exposure to pathogens. Don't let cats or dogs roam. Fleas and ticks are a concern, as well as exposure to other animals and their feces, and anything else the pet might eat off the street.

Keep the animal inside, and keep the toilet seat down so the pet does not use the fixture as a fountain. Feed the animal well, and make sure it does not get into the garbage.

Third, avoid all contact with feces.

Dr. McFarland offered additional recommendations for patients, including children, who undergo hematopoietic stem cell transplants (MMWR 2000;49[RR10]:1-128). Parents should be advised of the risks, but children don't need to be forced to part with their pets.

Animals should be fed high-quality commercial pet food, according to Dr. McFarland, and at the first suspicion of a pet's illness, the animal should be taken to the vet.

Even with these precautions, some animals are prohibited as pets. She listed all reptiles (with a warning against reptile fomites), ducklings or chicks, and exotic pets, including nonhuman primates.

For more information, including brochures to download, Dr. McFarland recommended referring parents to www.cdc.gov/healthypets.

prior to splenectomy, if possible. Afterward, these children also should receive annual influenza shots, she said.

Daily antibiotic prophylaxis is recommended, especially in the first 2 years after splenectomy.

However, Dr. McFarland said the randomized studies supporting its use were performed in young sickle cell anemia patients with functional asplenia.

Determining when to discontinue daily prophylaxis is difficult, she said, as there are no direct data for children with splenectomies. Physicians should discuss the risks and benefits with their patients. The recommended dosages are 125 mg of

penicillin V twice daily in children under age 5 and 250 mg twice daily in children over age 5; some experts use amoxicillin (20 mg/kg daily).

Empiric therapy is another option, often used if daily prophylaxis is discontinued. At the first sign of a fever, the parents administer a dose of oral antibiotics and then bring in the child “pronto” for further evaluation. Dr. McFarland recommended 50 mg/kg of amoxicillin/clavulanate potassium (Augmentin) divided into 2-3 dosages daily or an alternative, possibly a cephalosporin, if the child is allergic to penicillin.

Pneumococcal resistance to penicillin is

a concern, she said, and she urged physicians to find out the rate in their community. For sepsis cases, however, she recommended starting with vancomycin and a cephalosporin.

Without a spleen, patients also are at high risk for malaria and other insect-borne infections. Physicians should ask about mosquito and tick exposure and teach parents travel precautions.

Indeed, family education is a priority when caring for a child who has lost a spleen. “You need to give them something written, as you want them to understand the risk of infection,” she said. “And you want to do it more than once.” ■

MOBIC® (meloxicam)

the only once-daily prescription NSAID oral suspension for treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis.



MOBIC is a nonsteroidal anti-inflammatory drug (NSAID) indicated to help relieve the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) in adults. It is also indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course juvenile rheumatoid arthritis (JRA) in patients 2 years of age and older. MOBIC is available in 7.5 mg and 15 mg tablets and a 7.5 mg/5 mL oral suspension. For the treatment of OA and RA the recommended starting and maintenance dose of MOBIC is 7.5 mg once daily. Some adult patients may receive additional benefit by increasing the dose up to a maximum of 15 mg once daily. For the treatment of JRA, the recommended starting and maintenance dose of MOBIC oral suspension is 0.125 mg/kg, once daily, up to a maximum of 7.5 mg per day.

Carefully consider the potential benefits and risks of MOBIC and other treatment options before deciding to use MOBIC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.

MOBIC is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

MOBIC is contraindicated in patients with known hypersensitivity to meloxicam. It should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Please see following pages for Brief Summary of full Prescribing Information, including boxed WARNING.

Serious skin side effects can occur without warning, which may result in hospitalization and even death. Patients should be advised that if they develop any type of rash they should stop the drug immediately and contact their physicians as soon as possible.

Fluid retention and edema have been observed in some patients taking NSAIDs. Patients should be advised to promptly report signs or symptoms of unexplained weight gain or edema to their physicians. MOBIC should be used with caution in patients with fluid retention or heart failure.

NSAIDs, including MOBIC, can lead to onset of new hypertension or worsening of pre-existing hypertension.

Health care providers should refer to the full Prescribing Information before prescribing MOBIC to pregnant women. However, MOBIC should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus.

Patients should be informed of the warning signs and symptoms of hepatotoxicity.

NSAIDs may adversely impact the kidneys, resulting in renal papillary necrosis or other renal injury or overt renal decompensation. Patients should be monitored closely.

In clinical trials in adults with OA and RA, the most common side effects were diarrhea, indigestion, headache and flu-like symptoms. In clinical trials in children with JRA, the most common side effects were abdominal pain, vomiting, diarrhea, headache and pyrexia.

Coming Soon



MB-10808A